Transgenomic EGFR C797S Mutation Detection Assay
Transgenomic has launched its EGFR C797S Mutation Detection assay. The assay is based on the company's ICE COLD-PCR technology and detects the presence of the EGFR C797S mutation that is associated with resistance to new third-generation tyrosine kinase inhibitor therapies in development for non-small cell lung cancer. The high sensitivity of Transgenomic's ICP technology makes it possible to run the new assay using either tissue, blood, or serum samples, the company said. The test is currently available for research use only through Transgenomic's Biomarker Discovery Services group, and is expected to be available for clinical use through the company's oncology CLIA laboratory in Omaha, Nebraska later this year.
MDxHealth SelectMDx Liquid Biopsy Test
MDxHealth has launched its SelectMDx urine-based test for prostate cancer. SelectMDx for prostate cancer is a proprietary urine-based, molecular diagnostic test that offers a non-invasive method to identify patients at low risk for prostate cancer, the company said. The test will be commercially available in the US as a laboratory developed test.
GATC Biotech GatcLiquid Testing Services
GATC Biotech has launched its GatcLiquid testing services: OncoExome, OncoPanel, and OncoTarget. The three tests allow for highly sensitive detection of genomic alteration in circulating tumor DNA (ctDNA) to capture the entire heterogeneity of cancer. They provide clinical researchers the opportunity to interrogate a whole range of tumor-related mutations that help characterize a patient's cancer from a simple blood sample, the company said.
For more new products and services, please visit the New Products page on our website.